Modern perspectives of targeted therapy of asthma in children

Bronchial asthma is a disease that not only affects the quality of life in childhood, but also increases the risk of lung pathology in adult age, so timely and adequate treatment of asthma in children is an important task. In addition to traditional anti-inflammatory basic therapy (glucorticosteroids, bronchodilators, etc.), biological drugs are currently widely used to treat asthma in children. The most studied biological drug is omalizumab, a humanized monoclonal antibody to IgE. The article summarizes the experience of using omalizumab in children and provides short- and long-term results of its effectiveness and safety. Early criteria for the efficacy of therapy in children include reduction in symptoms and number of exacerbations. Therapy for 6-1 2 months led to a decrease in total IgE and an improvement in lung function as measured by spirography. No severe reactions to the drug were recorded. Treatment with omalizumab makes it possible to modify the course of bronchial asthma in children.